ReviewNature reviews. Rheumatology2016
Towards new avenues in the management of lupus glomerulonephritis.
Review in Nature reviews. Rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 85 citations in OpenAlex.
- Outcome of Patients With Lupus Nephritis Treated With an Anti-CD40 Monoclonal Antibody According to Kidney Biopsy Features.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Research progress in single‑cell omics technologies for kidney disease (Review).International journal of molecular medicine · 2026Review
- Role of lupus nephritis classification systems in everyday clinical practice: a questionnaire-based survey of the Renal Pathology Society (RPS).Clinical kidney journal · 2026Article
- Not So Benign: Revisiting Pure Membranous Lupus Nephritis.Journal of personalized medicine · 2025Review
- Anti-CD20 therapy in lupus nephritis: A revisit.Rheumatology and immunology research · 2025Article
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Clinical characteristics, prognosis, and predictive modeling in class IV ± V lupus nephritis.Frontiers in immunology · 2025Article
- The greatest contribution to medical science is the transformation from studying symptoms to studying their causes-the unrelenting legacy of Robert Koch and Louis Pasteur-and a causality perspective to approach a definition of SLE.Frontiers in immunology · 2024Article
- Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.Life (Basel, Switzerland) · 2023Review
- Amelioration of nephritis in receptor for advanced glycation end-products (RAGE)-deficient lupus-prone mice through neutrophil extracellular traps.Clinical immunology (Orlando, Fla.) · 2023Article
- Treatment of lupus nephritis: consensus, evidence and perspectives.Nature reviews. Rheumatology · 2023Review
- Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.Frontiers in immunology · 2022Review
- A single-cell survey of the human glomerulonephritis.Journal of cellular and molecular medicine · 2021Article
- Review
- Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov.Frontiers in medicine · 2021Article
- Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: A case report and review of literature.World journal of clinical cases · 2020Article
- Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology.Arthritis research & therapy · 2020Article
- Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases.JMA journal · 2020Review
- The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients.PloS one · 2020Article
- Glomerulonephritis in AKI: From Pathogenesis to Therapeutic Intervention.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal involvement in systemic lupus erythematosus (SLE) carries substantial morbidity and mortality. Conventional immunosuppressive agents (cyclophosphamide and azathioprine) have suboptimal efficacy and substantial toxicity. Mycophenolate mofetil has emerged as an alternative agent for both induction and maintenance therapy in lupus nephritis because of its reduced gonadal toxicity, despite its failure to demonstrate superiority over cyclophosphamide in pivotal studies. The calcineurin inhibitor tacrolimus has equivalent efficacy to cyclophosphamide and mycophenolate mofetil for inducing remission of lupus nephritis. Although rituximab has shown promise in refractory lupus nephritis, combining rituximab with mycophenolate mofetil as initial therapy offers no additional benefit. Considerable interethnic variation is evident in the efficacy and tolerability of the various immunosuppressive regimens, which necessitates individualized treatment and comparison of the efficacy of new regimens across different ethnic groups. For example, low-dose combinations of tacrolimus and mycophenolate mofetil seem to be more effective than pulse cyclophosphamide as induction therapy in Chinese patients. The same regimen has also been used successfully to treat refractory proliferative and membranous lupus nephritis in patients of various ethnic groups. Finally, novel serum and urinary biomarkers are being validated for diagnosis, prognostic stratification and early recognition of flares in lupus nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.